Drug interactions between Bydureon and Victoza
Interactions between your drugs
There were no interactions found in our database between Bydureon and Victoza - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.
- Victoza is a member of the drug class incretin mimetics.
- Victoza is used to treat the following conditions:
Drug and food interactions
Applies to: Bydureon (exenatide)
You should take exenatide twice a day, at any time within the 60 minutes (1 hour) before your morning and evening meals, or before the two main meals of the day, and at least 6 hours or more apart. You may experience decreased absorption of exenatide in the presence of food or other medications. Your other medications should be administered at least 1 hour before or 2 hours after your exenatide injection.
Applies to: Victoza (liraglutide)
Liraglutide may affect the absorption of other medications that you take by mouth. In some cases, this may affect how well and/or how fast those medications work, or it may make no difference. Talk to a healthcare provider if you have any questions or concerns, and contact your doctor if your symptoms worsen or your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
The recommended maximum number of medicines in the 'incretin-based therapies' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'incretin-based therapies' category:
- Bydureon (exenatide)
- Victoza (liraglutide)
Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.